PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Englman Cameron, Maffei Davide, Allen Clare, Kirkham Alex, Albertsen Peter, Kasivisvanathan Veeru, Baroni Ronaldo Hueb, Briganti Alberto, De Visschere Pieter, Dickinson Louise, Gómez Rivas Juan, Haider Masoom A, Kesch Claudia, Loeb Stacy, Macura Katarzyna J, Margolis Daniel, Mitra Anita M, Padhani Anwar R, Panebianco Valeria, Pinto Peter A, Ploussard Guillaume, Puech Philippe, Purysko Andrei S, Radtke Jan Philipp, Rannikko Antti, Rastinehad Art, Renard-Penna Raphaele, Sanguedolce Francesco, Schimmöller Lars, Schoots Ivo G, Shariat Shahrokh F, Schieda Nicola, Tempany Clare M, Turkbey Baris, Valerio Massimo, Villers Arnauld, Walz Jochen, Barrett Tristan, Giganti Francesco, Moore Caroline M
Аннотация
METHODS: A panel of 38 experts used the formal RAND/UCLA Appropriateness Method consensus methodology. Panellists scored 193 statements using a 1-9 agreement scale, where 9 means full agreement. A summary of agreement, uncertainty, or disagreement (derived from the group median score) and consensus (determined using the Interpercentile Range Adjusted for Symmetry method) was calculated for each statement and presented for discussion before individual rescoring.
KEY FINDINGS AND LIMITATIONS: Participants agreed that MRI scans must meet a minimum image quality standard (median 9) or be given a score of 'X' for insufficient quality. The current scan should be compared with both baseline and previous scans (median 9), with the PRECISE score being the maximum from any lesion (median 8). PRECISE 3 (stable MRI) was subdivided into 3-V (visible) and 3-NonV (nonvisible) disease (median 9). Prostate Imaging Reporting and Data System/Likert ≥3 lesions should be measured on T2-weighted imaging, using other sequences to aid in the identification (median 8), and whenever possible, reported pictorially (diagrams, screenshots, or contours; median 9). There was no consensus on how to measure tumour size. More research is needed to determine a significant size increase (median 9). PRECISE 5 was clarified as progression to stage ≥T3a (median 9).
CONCLUSIONS AND CLINICAL IMPLICATIONS: The updated PRECISE recommendations reflect expert consensus opinion on minimal standards and reporting criteria for prostate MRI in AS.